Novo Nordisk’s Semaglutide Data Blitz at ADA Targets Wider Therapeutic Role and Competitive Doubts

Novo Nordisk has arrived at the American Diabetes Association’s annual meeting in New Orleans armed with a broad dataset intended to do more than just refresh the scientific record. The Danish drugmaker is trying to reshape the conversation around semaglutide — from a weight-loss juggernaut to a multi-indication therapy that can hold its own against newer rivals. For investors who have watched the stock shed more than 40% over the past twelve months, the message is clear: this franchise has more to offer than what the current share price reflects.

The most immediately commercial argument comes from the COMPETE SWITCH analysis, a real-world study that directly compared what happens when patients on semaglutide 1 mg either increase their dose to 2 mg or switch to Eli Lilly’s tirzepatide. Drawing on a US claims database covering nearly 65,000 patients from January 2018 to September 2025, the data showed near-identical blood sugar control. After one year, 74.7% of those who titrated to semaglutide 2 mg achieved an HbA1c below 7%, versus 75.1% in the tirzepatide group, which started at 2.5 mg or 5 mg with allowed titration. On weight loss, semaglutide actually outperformed: 60.5% of patients losing at least 5% of body weight compared with 55.3% on tirzepatide. Novo Nordisk itself acknowledged the study’s limitations — it relies on administrative billing records, not a controlled trial — but the implication for prescribers is clear: staying with semaglutide is a credible option.

Beyond the competitive real-world data, the company rolled out a series of clinical updates that position semaglutide as a drug with effects far beyond the scale. New analyses from the landmark SELECT trial showed that weekly semaglutide 2.4 mg was associated with a 48% lower rate of obstructive sleep apnea events. Asthma-related adverse events fell by 42% compared with placebo. Inflammatory markers also improved: the high-sensitivity C-reactive protein level dropped by 38.9% by week 104. Pooled data from the STEP and OASIS programmes added another piece, with systolic blood pressure falling by an average of 5.48 mmHg in patients with uncontrolled hypertension. Meanwhile, the ESSENCE study demonstrated improvements in liver parameters and cardiometabolic risk factors in patients with metabolic dysfunction-associated steatohepatitis over 72 weeks.

The pipeline also made its case. Zenagamtide, a phase 2 candidate, achieved meaningful HbA1c reductions in type 2 diabetes patients and delivered weight loss of up to 14.6%. Closer to market is Wegovy HD: the FDA has already approved the higher 7.2 mg dose, which produced roughly 19% weight loss over 17 months. That compares with about 16% for the standard 2.4 mg dose. But the higher dose comes with a tolerability trade-off. More than 70% of patients in the high-dose group reported gastrointestinal side effects such as nausea or vomiting, underscoring the medical and commercial dilemma between greater efficacy and patient comfort.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Novo Nordisk is also trying to address one of the emerging concerns about GLP-1 therapies: that weight loss often comes at the cost of muscle mass. The company has struck a partnership with Veru to run the phase 2b PLATEAU study, testing Wegovy in combination with enobosarm, an oral selective androgen receptor modulator, in older patients with obesity. Novo Nordisk is providing the Wegovy and has secured a right of first negotiation for future combination rights.

Despite the data barrage, the equity remains under pronounced pressure. Shares closed Friday at €37.27, down 1.01% on the day. The stock is now 16.58% lower year-to-date, 41.55% below where it stood twelve months ago, and nearly 47% off its 52-week high of €70.13. The relative strength index sits at 48.3, indicating no clear short-term direction. The stock is trading above its 50-day moving average of €35.80 but well below the 200-day average of €41.66.

Part of that weakness stems from broader market doubts about growth momentum and pricing power in the GLP-1 space, especially with Eli Lilly’s tirzepatide encroaching on both diabetes and obesity turf. Novo Nordisk’s first-quarter 2026 results showed a 4% decline in adjusted revenue at constant exchange rates, although the obesity division itself grew 22%. The full-year outlook calls for a further adjusted revenue decline of between 4% and 12%.

Novo Nordisk at a turning point? This analysis reveals what investors need to know now.

A Goldman Sachs analysis flagged another long-term risk: competition from generic semaglutide after patent expirations starting in 2027. The note suggested that supply of peptide active ingredients will be a key battleground, with China currently leading in synthetic production. Novo Nordisk’s fermentation-based manufacturing, the bank argued, probably still holds a cost advantage.

For now, the medical evidence appears to support Novo Nordisk’s core thesis — that Wegovy and semaglutide are more than just weight-loss drugs. Whether that clinical breadth can translate into durable revenue growth, sustained margins, and a credible defence against generics is the question that will determine whether the equity can reclaim its former highs. The next test comes when European markets open on Monday, with the market digesting the ADA data and an investor webcast held Sunday evening local time.

Ad

Novo Nordisk Stock: New Analysis - 7 June

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69496313 |